Category: Historical

FDA Grants Genentech’s New Med for Breast Cancer

South San Francisco, CA   March 8, 2019 Genentech Press Release FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer — This Tecentriq combination is the first cancer immunotherapy regimen approved for breast…